Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.

Nounou MI, Adkins CE, Rubinchik E, Terrell-Hall TB, Afroz M, Vitalis T, Gabathuler R, Tian MM, Lockman PR.

Pharm Res. 2016 Dec;33(12):2930-2942. Epub 2016 Aug 15.

2.

Antimicrobial properties of MX-2401, an expanded-spectrum lipopeptide active in the presence of lung surfactant.

Dugourd D, Yang H, Elliott M, Siu R, Clement JJ, Straus SK, Hancock RE, Rubinchik E.

Antimicrob Agents Chemother. 2011 Aug;55(8):3720-8. doi: 10.1128/AAC.00322-11. Epub 2011 May 16.

3.

Mechanism of action and limited cross-resistance of new lipopeptide MX-2401.

Rubinchik E, Schneider T, Elliott M, Scott WR, Pan J, Anklin C, Yang H, Dugourd D, Müller A, Gries K, Straus SK, Sahl HG, Hancock RE.

Antimicrob Agents Chemother. 2011 Jun;55(6):2743-54. doi: 10.1128/AAC.00170-11. Epub 2011 Apr 4.

4.

Ex vivo skin infection model.

Rubinchik E, Pasetka C.

Methods Mol Biol. 2010;618:359-69. doi: 10.1007/978-1-60761-594-1_22.

PMID:
20094875
5.

Assay systems for measurement of anti-inflammatory activity.

Rubinchik E, Pasetka C.

Methods Mol Biol. 2010;618:349-58. doi: 10.1007/978-1-60761-594-1_21.

PMID:
20094874
6.

Novel antimicrobial lipopeptides with long in vivo half-lives.

Pasetka CJ, Erfle DJ, Cameron DR, Clement JJ, Rubinchik E.

Int J Antimicrob Agents. 2010 Feb;35(2):182-5. doi: 10.1016/j.ijantimicag.2009.10.013. Epub 2009 Dec 16.

PMID:
20006467
7.

Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models.

Rubinchik E, Dugourd D, Algara T, Pasetka C, Friedland HD.

Int J Antimicrob Agents. 2009 Nov;34(5):457-61. doi: 10.1016/j.ijantimicag.2009.05.003. Epub 2009 Jun 12.

PMID:
19524411
8.

Anti-inflammatory activity of cationic peptides: application to the treatment of acne vulgaris.

Marta Guarna M, Coulson R, Rubinchik E.

FEMS Microbiol Lett. 2006 Apr;257(1):1-6. Review.

9.
10.

Responsiveness of human skin mast cells to repeated activation: an in vitro study.

Rubinchik E, Shalit M, Levi-Schaffer F.

Allergy. 1998 Jan;53(1):14-9. Erratum in: Allergy 1998 May;53(5):547.

PMID:
9491224
11.

Regulation of the functional activity of mast cells and fibroblasts by mononuclear cells in murine and human chronic graft-vs.-host disease.

Levi-Schaffer F, Segal V, Barak V, Rubinchik E, Nagler A.

Exp Hematol. 1997 Mar;25(3):238-45.

PMID:
9091300
12.

Inhibition of proliferation of psoriatic and healthy fibroblasts in cell culture by selected Dead-sea salts.

Levi-Schaffer F, Shani J, Politi Y, Rubinchik E, Brenner S.

Pharmacology. 1996 May;52(5):321-8.

PMID:
8807676
13.

Interleukin-2 inhibits 3T3 fibroblast proliferation.

Rubinchik E, Levi-Schaffer F.

Life Sci. 1996;58(18):1509-17.

PMID:
8649180
14.

Modulations of histamine release from mast cells by interleukin-2 is affected by nedocromil sodium.

Rubinchik E, Norris A, Levi-Schaffer F.

Int J Immunopharmacol. 1995 Jul;17(7):563-70.

PMID:
8586484
15.

Mast cell role in fibrotic diseases.

Levi-Schaffer F, Rubinchik E.

Isr J Med Sci. 1995 Jul;31(7):450-3. Review. No abstract available.

PMID:
7607878
16.

Activated mast cells are fibrogenic for 3T3 fibroblasts.

Levi-Schaffer F, Rubinchik E.

J Invest Dermatol. 1995 Jun;104(6):999-1003.

17.

Human foreskin mast cell viability and functional activity is maintained ex vivo by coculture with fibroblasts.

Levi-Schaffer F, Kelav-Appelbaum R, Rubinchik E.

Cell Immunol. 1995 May;162(2):211-6.

PMID:
7743548
18.

Mast cell/fibroblast interactions.

Levi-Schaffer F, Rubinchik E.

Clin Exp Allergy. 1994 Nov;24(11):1016-21. Review. No abstract available.

PMID:
7874600
19.

Mast cells and fibroblasts: two interacting cells.

Rubinchik E, Levi-Schaffer F.

Int J Clin Lab Res. 1994;24(3):139-42. Review.

PMID:
7819593

Supplemental Content

Loading ...
Support Center